Related Experiment Videos
Molecular defects in Sanfilippo syndrome type A
1Department of Chemical Pathology, Women's and Children's Hospital, North Adelaide, Australia.
Human Molecular Genetics
|May 1, 1997
Summary
Sanfilippo A syndrome (MPS-IIIA) is a neurodegenerative disorder caused by sulphamidase deficiency. This study identified five mutations in the sulphamidase gene in MPS-IIIA patients, aiding molecular diagnostics and genotype-phenotype studies.
Area of Science:
- Genetics
- Biochemistry
- Neuroscience
Background:
- Sanfilippo A syndrome (mucopolysaccharidosis type IIIA, MPS-IIIA) is an inherited neurodegenerative disorder.
- It results from a deficiency in the lysosomal enzyme sulphamidase, crucial for heparan sulphate degradation.
Purpose of the Study:
- To investigate molecular defects in the sulphamidase gene of MPS-IIIA patients.
- To identify novel mutations and determine their incidence in patient populations.
Main Methods:
- RT-PCR amplification of the sulphamidase gene's coding region.
- Direct PCR sequencing to identify mutations.
- Oligonucleotide hybridization to determine mutation frequency in patients and controls.
Main Results:
- Identified one polymorphism (R456H), four novel mutations (S66W, R245H, E447K, 1307 del 9), and one known mutation (1284 del 11).
- R245H was the most frequent mutation (27% of alleles) in the patient population.
- The polymorphic variant R456H was present in both patients (38%) and controls (55%).
Conclusions:
- This study is the first to report molecular defects in MPS-IIIA patients.
- The identified mutations are crucial for developing molecular diagnostic tools for MPS-IIIA.
- Findings will facilitate research into genotype-phenotype correlations in Sanfilippo A syndrome.